TI
CDTX

Trexquant Investment’s Cidara Therapeutics CDTX Stock Holding History

Trexquant Investment’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-771
Closed -$80K – 962
2018
Q2 		$80K Sell
771
-871
-53% -$82.2K 0.01% 844
2018
Q1 		$131K Buy
1,642
+895
+120% +$122K 0.01% 1001
2017
Q4 		$102K Buy
+747
New +$113K 0.01% 1004
2017
Q3 		– Sell
-737
Closed -$110K – 792
2017
Q2 		$110K Buy
+737
New +$102K 0.03% 736

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Trexquant Investment's CDTX Position: Q3 2018 in Review

Trexquant Investment sold out of Cidara Therapeutics (CDTX) in Q3 2018, closing a stake of 771 shares — an estimated $80K sold.

Trexquant Investment first reported a position in CDTX in Q2 2017 and held it in 4 quarters. The position peaked at $131K in Q1 2018. 59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

  • Trexquant Investment reported no remaining Cidara Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Trexquant Investment sold 771 Cidara Therapeutics shares in Q3 2018, an estimated $80K.
  • Trexquant Investment first reported a position in Cidara Therapeutics in Q2 2017 and held it in 4 quarters.
  • Trexquant Investment's Cidara Therapeutics position peaked at $131K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Trexquant Investment's 13F filing for Q3 2018, filed 9 Nov 2018.